앞으로 몇 년동안 담도 폐쇄증 시장은 이 질환에 대한 인식이 높아지고 전 세계 의료비 지출이 증가함에 따라 변화할 것으로 예상됩니다.
기업과 연구기관들은 담도 폐쇄증 연구개발에 영향을 미칠 수 있는 도전과제를 평가하고 기회를 모색하기 위해 노력하고 있습니다. 개발 중인 치료법은 질환을 치료/개선하기 위한 새로운 접근법에 초점을 맞추었습니다. 주요 기업들이 담도 폐쇄증 치료제 개발에 참여하고 있습니다. 새로운 치료법의 등장은 담도 폐쇄증 시장에 큰 영향을 미칠 것으로 예상됩니다.
이 보고서는 주요 7개국의 담도 폐쇄증 시장을 조사했으며, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2034년까지 시장 규모 예측, 의료 미충족 수요 등의 정보를 제공합니다.
목차
제1장 주요 인사이트
제2장 담도 폐쇄증 주요 요약
제3장 담도 폐쇄증 경쟁 정보 분석
제4장 담도 폐쇄증 : 시장 개요
제5장 담도 폐쇄증 : 질환 배경과 개요
제6장 환자 동향
제7장 담도 폐쇄증의 역학과 환자 인구
- 역학 주요 조사 결과
- 전제와 근거 : 주요 7개국
- 역학 시나리오 : 주요 7개국
- 미국
- 유럽 5개국
- 일본역학
제8장 치료 알고리즘, 현재 치료, 의료 행위
제9장 미충족 요구
제10장 담도 폐쇄증 치료의 주요 평가항목
제11장 출시 제품
제12장 새로운 치료법
제13장 담도 폐쇄증 : 주요 7개국 시장 분석
제14장 속성 분석
제15장 주요 7개국 : 시장 전망
- 미국 : 시장 규모
- 유럽 5개국 : 시장 규모와 전망
- 독일 : 시장 규모
- 프랑스 : 시장 규모
- 이탈리아 : 시장 규모
- 스페인 : 시장 규모
- 영국 : 시장 규모
- 일본 : 시장 규모
제16장 담도 폐쇄증 접근 및 상환 개요
제17장 KOL(Key Opinion Leader)의 견해
제18장 시장 성장 촉진요인
제19장 시장 성장 억제요인
제20장 부록
제21장 DelveInsight의 서비스 내용
제22장 면책사항
제23장 DelveInsight에 대해
LSH
DelveInsight's "Biliary Atresia - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Biliary Atresia market report provides current treatment practices, emerging drugs, Biliary Atresia market share of the individual therapies, current and forecasted Biliary Atresia market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Biliary Atresia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered:
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2020-2034
Biliary Atresia Disease Understanding and Treatment Algorithm
The DelveInsight Biliary Atresia market report gives a thorough understanding of the Biliary Atresia by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Biliary Atresia.
Treatment
It covers the details of conventional and current medical therapies available in the Biliary Atresia market for the treatment of the condition. It also provides Biliary Atresia treatment algorithms and guidelines in the United States, Europe, and Japan.
Biliary Atresia Epidemiology
The Biliary Atresia epidemiology division provide insights about historical and current Biliary Atresia patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Biliary Atresia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.
Country Wise-Biliary Atresia Epidemiology
The epidemiology segment also provides the Biliary Atresia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Biliary Atresia Drug Chapters
Drug chapter segment of the Biliary Atresia report encloses the detailed analysis of Biliary Atresia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Biliary Atresia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Marketed Drugs
The report provides the details of the marketed product available for Biliary Atresia treatment.
Biliary Atresia Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Biliary Atresia treatment.
Biliary Atresia Market Outlook
The Biliary Atresia market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Biliary Atresia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Biliary Atresia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Biliary Atresia market in 7MM is expected to change in the study period 2020-2034.
Key Findings
This section includes a glimpse of the Biliary Atresia market in 7MM.
The United States Market Outlook
This section provides the total Biliary Atresia market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Biliary Atresia market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Biliary Atresia market size and market size by therapies in Japan is also mentioned.
Biliary Atresia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Biliary Atresia market or expected to get launched in the market during the study period 2020-2034. The analysis covers Biliary Atresia market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Biliary Atresia Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Biliary Atresia key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Biliary Atresia emerging therapies.
Reimbursement Scenario in Biliary Atresia
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SME's opinion working in Biliary Atresia domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Biliary Atresia market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Biliary Atresia Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report:
- The report covers the descriptive overview of Biliary Atresia, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Biliary Atresia epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Biliary Atresia are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Biliary Atresia market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Biliary Atresia market
Report Highlights:
- In the coming years, Biliary Atresia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Biliary Atresia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Biliary Atresia. Launch of emerging therapies will significantly impact the Biliary Atresia market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Biliary Atresia
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Biliary Atresia Report Insights
- Patient Population
- Therapeutic Approaches
- Biliary Atresia Pipeline Analysis
- Biliary Atresia Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Biliary Atresia Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Biliary Atresia Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Biliary Atresia Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions:
Market Insights:
- What was the Biliary Atresia market share (%) distribution in 2020 and how it would look like in 2034?
- What would be the Biliary Atresia total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Biliary Atresia market size during the forecast period (2024-2034)?
- At what CAGR, the Biliary Atresia market is expected to grow in 7MM during the forecast period (2020-2034)?
- What would be the Biliary Atresia market outlook across the 7MM during the forecast period (2020-2034)?
- What would be the Biliary Atresia market growth till 2032, and what will be the resultant market Size in the year 2034?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What is the disease risk, burden and unmet needs of the Biliary Atresia?
- What is the historical Biliary Atresia patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Biliary Atresia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Biliary Atresia?
- Out of all 7MM countries, which country would have the highest prevalent population of Biliary Atresia during the forecast period (2020-2034)?
- At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Biliary Atresia treatment, along with the approved therapy?
- What are the current treatment guidelines for the treatment of Biliary Atresia in the USA, Europe, and Japan?
- What are the Biliary Atresia marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Biliary Atresia?
- How many therapies are developed by each company for Biliary Atresia treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Biliary Atresia treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Biliary Atresia therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Biliary Atresia and their status?
- What are the key designations that have been granted for the emerging therapies for Biliary Atresia?
- What are the global historical and forecasted market of Biliary Atresia?
Reasons to buy:
- The report will help in developing business strategies by understanding trends shaping and driving the Biliary Atresia market
- To understand the future market competition in the Biliary Atresia market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Biliary Atresia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Biliary Atresia market
- To understand the future market competition in the Biliary Atresia market
Table of Contents
1. Key Insights
2. Executive Summary of Biliary Atresia
3. Competitive Intelligence Analysis for Biliary Atresia
4. Biliary Atresia: Market Overview at a Glance
- 4.1. Biliary Atresia Total Market Share (%) Distribution in 2020
- 4.2. Biliary Atresia Total Market Share (%) Distribution in 2034
5. Biliary Atresia: Disease Background and Overview
- 5.1. Introduction
- 5.2. Sign and Symptoms
- 5.3. Pathophysiology
- 5.4. Risk Factors
- 5.5. Diagnosis
6. Patient Journey
7. Biliary Atresia Epidemiology and Patient Population
- 7.1. Epidemiology Key Findings
- 7.2. Assumptions and Rationale: 7MM
- 7.3. Epidemiology Scenario: 7MM
- 7.3.1. Biliary Atresia Epidemiology Scenario in the 7MM (2020-2034)
- 7.4. United States Epidemiology
- 7.4.1. Biliary Atresia Epidemiology Scenario in the United States (2020-2034)
- 7.5. EU-5 Country-wise Epidemiology
- 7.5.1. Germany Epidemiology
- 7.5.1.1. Biliary Atresia Epidemiology Scenario in Germany (2020-2034)
- 7.5.2. France Epidemiology
- 7.5.2.1. Biliary Atresia Epidemiology Scenario in France (2020-2034)
- 7.5.3. Italy Epidemiology
- 7.5.3.1. Biliary Atresia Epidemiology Scenario in Italy (2020-2034)
- 7.5.4. Spain Epidemiology
- 7.5.4.1. Biliary Atresia Epidemiology Scenario in Spain (2020-2034)
- 7.5.5. United Kingdom Epidemiology
- 7.5.5.1. Biliary Atresia Epidemiology Scenario in the United Kingdom (2020-2034)
- 7.5.6. Japan Epidemiology
- 7.5.6.1. Biliary Atresia Epidemiology Scenario in Japan (2020-2034)
8. Treatment Algorithm, Current Treatment, and Medical Practices
- 8.1. Biliary Atresia Treatment and Management
- 8.2. Biliary Atresia Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Biliary Atresia Treatment
11. Marketed Products
- 11.1. List of Marketed Products in the 7MM
- 11.2. Drug Name: Company Name
- 11.2.1. Product Description
- 11.2.2. Regulatory Milestones
- 11.2.3. Other Developmental Activities
- 11.2.4. Pivotal Clinical Trials
- 11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
- 12.1. Key Cross
- 12.2. Drug Name: Company Name
- 12.2.1. Product Description
- 12.2.2. Other Developmental Activities
- 12.2.3. Clinical Development
- 12.2.4. Safety and Efficacy
- 12.2.5. Product Profile
List to be continued in report
13. Biliary Atresia: Seven Major Market Analysis
- 13.1. Key Findings
- 13.2. Biliary Atresia Market Size in 7MM
- 13.3. Biliary Atresia Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
- 15.1. United States: Market Size
- 15.1.1. Biliary Atresia Total Market Size in the United States
- 15.1.2. Biliary Atresia Market Size by Therapies in the United States
- 15.2. EU-5 countries: Market Size and Outlook
- 15.3. Germany Market Size
- 15.3.1. Biliary Atresia Total Market Size in Germany
- 15.3.2. Biliary Atresia Market Size by Therapies in Germany
- 15.4. France Market Size
- 15.4.1. Biliary Atresia Total Market Size in France
- 15.4.2. Biliary Atresia Market Size by Therapies in France
- 15.5. Italy Market Size
- 15.5.1. Biliary Atresia Total Market Size in Italy
- 15.5.2. Biliary Atresia Market Size by Therapies in Italy
- 15.6. Spain Market Size
- 15.6.1. Biliary Atresia Total Market Size in Spain
- 15.6.2. Biliary Atresia Market Size by Therapies in Spain
- 15.7. United Kingdom Market Size
- 15.7.1. Biliary Atresia Total Market Size in the United Kingdom
- 15.7.2. Biliary Atresia Market Size by Therapies in the United Kingdom
- 15.8. Japan Market Outlook
- 15.8.1. Japan Market Size
- 15.8.2. Biliary Atresia Total Market Size in Japan
- 15.8.3. Biliary Atresia Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Biliary Atresia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
- 20.1. Bibliography
- 20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
The table of contents is not exhaustive; the final content may vary.
